DarioHealth Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
Rhea-AI Summary
DarioHealth (NASDAQ: DRIO) reported Q4 2025 revenue of $5.2M and full-year 2025 revenue of $22.4M versus $27.0M in 2024, driven by a legacy client nonrenewal after the Twill acquisition.
Key metrics: GAAP gross margin 57%, pipeline $122M, contracted/late-stage ARR $12.9M, cash $26M, and full-year operating expenses down 31% to $49.3M.
Positive
- GAAP gross margin improved to 57% (2025 vs 49% in 2024)
- Contracted and late-stage ARR $12.9M expected to convert in 2026–2027
- Commercial pipeline $122M across ~230 B2B2C opportunities
- Full-year operating expenses down 31% to $49.3M, improving loss trajectory
- Cash and short-term deposits of $26M at year-end 2025
Negative
- Full-year revenue decline of ~17% to $22.4M from $27.0M in 2024
- Operating loss remained $36.7M for full-year 2025
- Q4 non-GAAP net loss increased 32% year-over-year to $6.5M
- Revenue impacted materially by a single legacy client nonrenewal from Twill acquisition
News Market Reaction – DRIO
In the Mar 19 session, DRIO declined 7.73%, reflecting a notable negative market reaction. Argus tracked a trough of -17.8% from its starting point during tracking. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility. Trading volume was elevated at 2.0x the daily average, suggesting increased selling activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Nov 13 | Q3 2025 earnings | Positive | -15.6% | Reported margin strength and ARR focus but shares fell after results. |
| Aug 12 | Q2 2025 earnings | Positive | -14.8% | Revenue decline but strong cost cuts and pipeline growth; stock dropped. |
| May 14 | Q1 2025 earnings | Positive | -8.5% | Higher margins and lower opex with equity raise; shares moved lower. |
| Mar 10 | FY 2024 earnings | Positive | -8.0% | Strong revenue and client growth plus financing; stock still declined. |
| Nov 07 | Q3 2024 earnings | Positive | +0.5% | Strong quarterly growth and loss reduction led to a small gain. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Earnings releases have mostly been received negatively despite margin and efficiency improvements, with four of the last five earnings events selling off on generally constructive fundamentals.
Over the last five earnings cycles from Q3 2024 through Q3 2025, DarioHealth shifted from rapid top-line growth to an ARR- and margin-focused model. Revenue decelerated in 2025, but gross margins and operating efficiency improved, supported by pipeline and client growth and multiple capital raises. Despite this, the stock typically reacted negatively to earnings, with an average move of about -9.27%, underscoring a history of skeptical market responses to updates similar to today’s full-year 2025 report.
Key Terms
annual recurring revenue financial
arr financial
gaap financial
non-gaap financial
b2b2c financial
cares act regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Fourth quarter 2025 revenues grew sequentially to
$5.2 million $5.0 million - 2025 full-year revenue was
$22.4 million , compared to$27.0 million in 2024, due entirely to a scope change and nonrenewal from a single legacy client that came through the Twill, Inc. ("Twill") acquisition — unrelated to demand — partially offset by organic revenue growth - The 2025 sales season — Dario's strongest on record — generated $12.9 million in contracted and late stage, annual recurring revenue ("ARR") set to contribute revenue in 2026 and 2027 and position the Company for a high-growth trajectory
- GAAP gross margins increased to
57% in 2025 from49% in 2024 and Non-GAAP gross margins have sustained at80% for 2 years on the core B2B2C business - Fourth quarter 2025 delivered the lowest operating expense run-rate on both a GAAP and Non-GAAP basis since Twill's acquisition, reducing Non-GAAP operating expenses by
28% year-over-year, from$12.4 million $9.0 million - Pipeline of commercial opportunities grew to
$122 million - Increased demand for Dario's musculoskeletal ("MSK") product in the B2C market, with
36% growth in the fourth quarter of 2025 and continued expansion expected in international markets - Dario will host an investor conference call and webcast at 8:30 a.m. ET today
"2025 was our strongest commercial year on record — 85 new agreements signed and contracted and late stage ARR contracts representing
"As for AI, Dario owns the entire vertical value chain down to the clinical data itself – and the value of AI is determined entirely by the quality of data it runs on. Our platform spans proprietary hardware that generates continuous physiological data, intelligent personalized interventions, coaching, and analytics — all built on 13 billion real-world data points across longitudinal member journeys. We do not license our data, rent our AI, or depend on third-party content. We believe that ownership is a structural competitive advantage that strengthens with every new member and every new data point."
Commercial Momentum Continues as Dario Delivers Savings to Payers and Employers & Improved Health Outcomes to Members:
- In 2025 Dario signed 85 new contracts, many of which are starting to contribute revenue in 2026, with average client and contract size increasing 2X-10X compared to its historical average, more than doubling its new account target for the year. The majority of new contracts were for Dario's multi-condition platforms — the primary driver behind the 2x–10x expansion in average contract size.
- Pipeline of commercial opportunities increased to
$122 million 70% of pipeline opportunities are multi-condition, reflecting materially higher average contract values per opportunity compared to single-condition point solutions. - Dario delivers more clinical proof of ROI than any other digital health company with 100+ scientific studies including peer-reviewed journal publications and conference abstracts, demonstrating the Company's leadership in delivering rigorously validated outcomes for employers, health plans and their members.
- The launch of AI-driven DarioIQ™ reflects years of innovation in data science, engineering and clinical design backed by Dario's proprietary AI models and 13 billion real-world data points, further reinforcing Dario's position as a leader in digital health.
- Dario's oral GLP-1 digital health solution is positioned to amplify the positive impacts of GLP-1 medication, improving ROI for employers and health plans in one of the fastest growing expense centers for payers.
"We are seeing strong engagement from large payers and employers across the
"What is driving growth and what makes our model structurally different is that it compounds at two levels simultaneously. At the client level, channel partnerships give us access to millions of covered lives through a single commercial relationship, eliminating the account-by-account selling that we believe limits many competitors and reduces our cost of acquisition. At the member level, our multi-condition platform means a far greater share of each client's population qualifies for Dario — resulting in more members reached, more members enrolled, and potentially more revenue generated within the same account. One expands how many accounts we can reach, while the other expands how many members we can serve within each account. That is the compounding."
"Through channel partnerships with organizations such as Solera, Amwell, and leading national health plans including Aetna, we now have access to approximately 116 million covered lives. As these ecosystems expand, we anticipate that they will allow Dario to reach significantly larger populations without proportional increases in sales infrastructure."
"Quarter-over-Quarter Revenue Growth and Continued Operating Expense (OpEx) Improvement:
- Fourth quarter revenues grew quarter-over-quarter to
$5.2 million $5.0 million - Gross margin increased year-over-year to
57% in 2025, from49% in 2024. - Cash and short-term deposit balance of
$26 million - Net cash used in operating activities declined from
$38.6 million $25.9 million 33% reduction. - Operating expenses continue to decrease — fourth quarter 2025 total operating expense declined
28% to$11.4 million 9% quarter-over-quarter; full year 2025 total operating expense declined by31% to$49.3 million - Continued narrowing in operating loss — fourth quarter total operating loss declined
27% to$8.6 million 10% quarter-over-quarter; full year 2025 operating loss declined by37% to$36.7 million - Non–GAAP operating loss is expected to decrease by approximately
30% in 2026, targeting towards cashflow breakeven by mid-2027 based on large scale channel partner contracted and near-closing ARR, increasing commercial pipeline and reductions in operating expenses.
"Our financial trending continues to improve as operating expenses decline and our core B2B2C ARR business is contributing approximately
Financial Results for the Three Months Ended December 31, 2025
Revenue for the three months ended December 31, 2025 was
Gross profit for the three months ended December 31, 2025 was
Non-GAAP gross profit, excluding
Total operating expenses for the three months ended December 31, 2025, were
Non-GAAP operating expenses (excluding stock-based compensation, acquisition related expenses, depreciation and amortization expenses) for the three months ended December 31, 2025, were
Operating loss for the three months ended December 31, 2025, was
Non-GAAP operating loss (excluding stock-based compensation, acquisition-related expenses, and depreciation and amortization) for the three months ended December 31, 2025 was
Net loss was
Non-GAAP net loss (excluding stock-based compensation, acquisition related expenses, depreciation and amortization expenses) for the three months ended December 31, 2025 increased by
A reconciliation of GAAP to non-GAAP measures has been provided in the financial statement tables included in this press release. An explanation of these measures is also included below under the heading "Non-GAAP Financial Measures."
Financial Results for the Year Ended December 31, 2025
Revenues for the year ended December 31, 2025 were
Gross profit for the year ended December 31, 2025, was
Non-GAAP gross profit, excluding
Total operating expenses for the year ended December 31, 2025, were
Non-GAAP operating expenses (excluding stock-based compensation, acquisition-related expenses, depreciation and amortization expenses) for the year ended December 31, 2025, were
Operating loss for the year ended December 31, 2025, was
Non-GAAP operating loss (excluding stock-based compensation, acquisition related expenses, depreciation and amortization expenses) for the year ended December 31, 2025 was
Net loss was
Non-GAAP net loss (excluding stock-based compensation, acquisition-related expenses, and depreciation and amortization) for the year ended December 31, 2025 was
A reconciliation of GAAP to non-GAAP measures has been provided in the financial statement tables included in this press release. An explanation of these measures is also included below under the heading "Non-GAAP Financial Measures."
Conference Call Details
Date: Thursday, March 19th, 2026, 8:30 a.m. Eastern Time
Dial-in Number: 1-800-717-1738 (domestic) or 1-646-307-1865 (international)
Call me™: https://emportal.ink/4sksMwG
Participants can use the dial-in numbers above and be answered by an operator OR click the Call me™ link for instant telephone access to the event. This link will be made active 15 minutes prior to the scheduled start time.
Webcast link: https://viavid.webcasts.com/starthere.jsp?ei=1748263&tp_key=02d7c540f8
Participants are asked to dial in approximately 10 minutes prior to the start of the event. A replay of the call will be available approximately three hours after completion of the conference call through Thursday, April 2nd, 2026. To listen to the replay, dial 1-844-512-2921 (domestic) or 1-412-317-6671 (international) and use replay passcode 1191893.
About DarioHealth Corp. (NASDAQ: DRIO)
DarioHealth Corp. (NASDAQ: DRIO) is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric, multi-chronic condition digital therapeutics platform. Dario's platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain and behavioral health.
Dario's user-centric platform offers people continuous and customized care for their health, disrupting the traditional episodic approach to healthcare. This approach empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention and results and making the right thing to do the easy thing to do.
Dario provides its highly user-rated solutions globally to health plans and other payers, self-insured employers, providers of care and consumers. To learn more about Dario and its digital health solutions, or for more information, visit http://dariohealth.com.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements in this press release when it discusses its expectation that agreements entered into in 2025 will provide recurring revenue in 2026 and 2027, positioning the Company for a high-growth trajectory; its belief that increased demand for the Company's MSK product in the B2C market will result in expansion in international markets; its belief that the Company's model will provide compounding growth resulting in an expected increase in account outreach and growth, member enrollment and resulting revenue, increased through client collaborations and member enrollment; its belief that the Company's oral GLP-1 digital health solution is positioned to amplify the positive impacts of GLP-1 medication, improving ROI for employers and health plans; its belief that the Company's channel partnerships will expand and its expectation that such expansion will allow the Company to reach significantly larger populations without proportional increases in sales infrastructure; and its expectation that the Company will reduce its operating loss by
Non-GAAP Financial Measures
We have provided financial information in this release that has not been prepared in accordance with Generally Accepted Accounting Principles (GAAP). These non-GAAP financial measures are not based on any standardized methodology prescribed by GAAP and are not necessarily comparable to similar measures presented by other companies. We use these non-GAAP financial measures internally in analyzing our financial results and believe they are useful to investors, as a supplement to GAAP measures, in evaluating our ongoing operational performance. We believe that the use of these non-GAAP financial measures provides an additional tool for investors to use in evaluating ongoing operating results and trends and in comparing our financial results with peer companies, many of which present similar non-GAAP financial measures to investors.
Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. Investors are encouraged to review the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures provided in the financial statement tables below.
Operating expenses (non-GAAP). Our presentation of non-GAAP operating expenses excludes stock-based compensation expenses, amortization of acquisition-related expenses and depreciation of fixed assets. Due to varying available valuation methodologies, subjective assumptions, and the variety of equity instruments that can impact a company's non-cash operating expenses, we believe that providing non-GAAP financial measures that exclude non-cash expenses provides us with an important tool for financial and operational decision making and for evaluating our own core business operating results over different periods of time.
Net loss (non-GAAP). Our presentation of adjusted net loss excludes the effect of certain items that are non-GAAP financial measures. Adjusted net loss represents net loss determined under GAAP without regard to stock-based compensation expenses, depreciation and impairment expense, amortization of acquired technology and brand, financial (income) expenses, net, income tax, and acquisition costs. We believe these measures provide useful information to management and investors for analysis of our operating results.
DARIOHEALTH CORP. AND ITS SUBSIDIARIES | ||||||
CONSOLIDATED BALANCE SHEETS | ||||||
| ||||||
December 31, | December 31, | |||||
2025 | 2024 | |||||
ASSETS | ||||||
CURRENT ASSETS: | ||||||
Cash and cash equivalents | $ | 21,803 | $ | 27,764 | ||
Short-term bank deposits | 4,214 | 697 | ||||
Short-term restricted bank deposits | 229 | 175 | ||||
Trade receivables, net | 2,144 | 4,804 | ||||
Inventories | 4,316 | 4,753 | ||||
Other accounts receivable and prepaid expenses | 2,361 | 2,336 | ||||
Total current assets | 35,067 | 40,529 | ||||
NON-CURRENT ASSETS: | ||||||
Deposits | 80 | 79 | ||||
Operating lease right of use assets | 717 | 1,065 | ||||
Long-term assets | 304 | 313 | ||||
Property and equipment, net | 549 | 709 | ||||
Intangible assets, net | 15,931 | 18,762 | ||||
Goodwill | 57,427 | 57,427 | ||||
Total non-current assets | 75,008 | 78,355 | ||||
Total assets | $ | 110,075 | $ | 118,884 | ||
DARIOHEALTH CORP. AND ITS SUBSIDIARIES | ||||||
CONSOLIDATED BALANCE SHEETS | ||||||
December 31, | December 31, | |||||
2025 | 2024 | |||||
LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||
CURRENT LIABILITIES: | ||||||
Trade payables | $ | 2,928 | $ | 3,045 | ||
Deferred revenues | 714 | 1,583 | ||||
Operating lease liabilities | 430 | 504 | ||||
Other accounts payable and accrued expenses | 5,251 | 6,052 | ||||
Current maturity of long-term loan | — | 5,451 | ||||
Total current liabilities | 9,323 | 16,635 | ||||
NON-CURRENT LIABILITIES | ||||||
Operating lease liabilities | 571 | 765 | ||||
Long-term loan | 30,747 | 23,472 | ||||
Warrant liability | 1,466 | 5,968 | ||||
Other long-term liabilities | 46 | 25 | ||||
Total non-current liabilities | 32,830 | 30,230 | ||||
STOCKHOLDERS' EQUITY | ||||||
Common stock of | 4 | 4 | ||||
Preferred stock of | *) - | *) - | ||||
Additional paid-in capital | 519,996 | 462,358 | ||||
Accumulated deficit | (452,078) | (390,343) | ||||
Total stockholders' equity | 67,922 | 72,019 | ||||
Total liabilities and stockholders' equity | $ | 110,075 | $ | 118,884 | ||
*) Represents an amount lower than | ||||||
DARIOHEALTH CORP. AND ITS SUBSIDIARIES | ||||||
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS | ||||||
Year ended | ||||||
December 31, | ||||||
2025 | 2024 | |||||
Revenues: | ||||||
Services | $ | 14,929 | $ | 20,197 | ||
Consumer hardware | 7,430 | 6,843 | ||||
Total revenues | 22,359 | 27,040 | ||||
Cost of revenues: | ||||||
Services | 2,900 | 3,606 | ||||
Consumer hardware | 5,124 | 5,139 | ||||
Amortization of acquired intangible assets | 1,670 | 5,028 | ||||
Total cost of revenues | 9,694 | 13,773 | ||||
Gross profit | 12,665 | 13,267 | ||||
Operating expenses: | ||||||
Research and development | $ | 13,791 | $ | 24,179 | ||
Sales and marketing | 20,338 | 26,350 | ||||
General and administrative | 15,191 | 20,482 | ||||
Total operating expenses | 49,320 | 71,011 | ||||
Operating loss | 36,655 | 57,744 | ||||
Interest expenses | 3,020 | — | ||||
Other financial expenses (income), net | 1,934 | (13,145) | ||||
Total financial expenses (income), net | 4,954 | (13,145) | ||||
Loss before taxes | 41,609 | 44,599 | ||||
Income taxes (benefit) | 105 | (1,852) | ||||
Net loss | $ | 41,714 | $ | 42,747 | ||
Deemed dividend (contribution) | $ | 20,021 | $ | (1,765) | ||
Net loss attributable to common shareholders | $ | 61,735 | $ | 40,982 | ||
Net loss per share: | ||||||
Basic and diluted loss per share of common stock | $ | 10.12 | $ | 12.27 | ||
Weighted average number of common stock used in computing | 3,982,956 | 2,451,971 | ||||
DARIOHEALTH CORP. AND ITS SUBSIDIARIES | ||||||
CONSOLIDATED STATEMENTS OF CASH FLOWS | ||||||
Year ended | ||||||
December 31, | ||||||
2025 | 2024 | |||||
Cash flows from operating activities: | ||||||
Net loss | $ | (41,714) | $ | (42,747) | ||
Adjustments required to reconcile net loss to net cash used in operating activities: | ||||||
Stock-based compensation | 9,365 | 15,796 | ||||
Change in operating lease right of use assets | 421 | 907 | ||||
Amortization of acquired intangible assets | 2,831 | 6,100 | ||||
Changes in operating assets and liabilities, net of effects of businesses acquired: | ||||||
Depreciation and impairment | 307 | 1,327 | ||||
Decrease in trade receivables, net | 2,660 | 1,680 | ||||
Increase in other accounts receivable, prepaid expense and long-term assets | (16) | (80) | ||||
Decrease in inventories | 437 | 308 | ||||
Decrease in trade payables | (122) | (496) | ||||
Decrease in other accounts payable and accrued expenses | (780) | (3,483) | ||||
Decrease in deferred revenues | (869) | (156) | ||||
Change in operating lease liabilities | (341) | (1,150) | ||||
Change in fair value of warrant liability | (1,681) | (16,504) | ||||
Accrued interest on short term bank deposits | (14) | — | ||||
Non-cash financial expenses | 2,933 | 516 | ||||
Other | 642 | (580) | ||||
Net cash used in operating activities | (25,941) | (38,562) | ||||
Cash flows from investing activities: | ||||||
Purchase of property and equipment, net | (142) | (138) | ||||
Investments in short-term bank deposits | (4,200) | — | ||||
Payments for business acquisitions, net of cash acquired | — | (8,796) | ||||
Net cash used in investing activities | (4,342) | (8,934) | ||||
Cash flows from financing activities: | ||||||
Proceeds from issuance of common stock and prefunded warrants, net of issuance costs | 17,374 | — | ||||
Proceeds from issuance of preferred stock, net of issuance costs | 6,754 | 38,531 | ||||
Proceeds from borrowings on credit agreement, net | 31,700 | — | ||||
Repayment of long-term loan | (31,515) | — | ||||
Net cash provided by financing activities | 24,313 | 38,531 | ||||
Increase (decrease) in cash, cash equivalents and restricted cash and cash equivalents | (5,970) | (8,965) | ||||
Effect of exchange rate differences on cash, cash equivalents and restricted cash and | 9 | (68) | ||||
Cash, cash equivalents and restricted cash and cash equivalents at beginning of period | 27,764 | 36,797 | ||||
Cash, cash equivalents and restricted cash and cash equivalents at end of period | $ | 21,803 | $ | 27,764 | ||
Supplemental disclosure of cash flow information: | ||||||
Cash paid during the period for interest on long-term loan | $ | 3,493 | $ | 3,927 | ||
Non-cash activities: | ||||||
Right-of-use assets obtained in exchange for lease liabilities | $ | 73 | $ | 428 | ||
Purchase of property and equipment on credit | 5 | — | ||||
Exercise of pre-funded warrants to common stock upon acquisition | $ | 2,821 | $ | 2,225 | ||
Reconciliation of Operating Loss, Net Loss and Operating Expenses to Adjusted | ||||||||
Operating Loss, Net Loss and Operating Expenses (Non-GAAP) | ||||||||
Three months ended December 31, 2025 | ||||||||
GAAP | Stock-Based | Amortization of | Non-GAAP | |||||
Cost of Revenues | $ | 2,427 | (4) | (184) | 2,239 | |||
Gross Profit | 2,804 | 4 | 184 | 2,992 | ||||
Research and development | 2,634 | (267) | (31) | 2,336 | ||||
Sales and Marketing | 4,630 | (300) | (308) | 4,022 | ||||
General and Administrative | 4,102 | (1,467) | (10) | 2,625 | ||||
Total Operating Expenses | 11,366 | (2,034) | (349) | 8,983 | ||||
Operating Loss | $ | (8,562) | 2,038 | 533 | (5,991) | |||
Financing expenses | 386 | - | - | 386 | ||||
Income Tax | 83 | - | - | 83 | ||||
Net Loss | $ | (9,031) | 2,038 | 538 | (6,460) | |||
Reconciliation of Operating Loss, Net Loss and Operating Expenses to Adjusted | ||||||||
Operating Loss, Net Loss and Operating Expenses (Non-GAAP) | ||||||||
Three months ended December 31, 2024 | ||||||||
GAAP | Stock-Based | Amortization of | Non-GAAP | |||||
Cost of Revenues | $ | 3,402 | (8) | (1,302) | 2,092 | |||
Gross Profit | 4,202 | (8) | 1,302 | 5,512 | ||||
Research and development | 5,281 | (985) | (51) | 4,245 | ||||
Sales and Marketing | 5,575 | (536) | (325) | 4,714 | ||||
General and Administrative | 5,014 | (1,061) | (474) | 3,479 | ||||
Total Operating Expenses | 15,870 | (2,582) | (850) | 12,438 | ||||
Operating Loss | $ | (11,668) | 2,590 | 2,152 | (6,926) | |||
Financing expenses | (2,191) | - | - | (2,191) | ||||
Income Tax | 155 | - | - | 155 | ||||
Net Loss | $ | (9,632) | 2,590 | 2,152 | (4,890) | |||
Reconciliation of Operating Loss, Net Loss and Operating Expenses to Adjusted | ||||||||
Operating Loss, Net Loss and Operating Expenses (Non-GAAP) | ||||||||
Twelve months ended December 31, 2025 | ||||||||
GAAP | Stock-Based | Amortization of | Non-GAAP | |||||
Cost of Revenues | $ | 9,694 | (26) | (1,713) | 7,955 | |||
Gross Profit | 12,665 | 26 | 1,713 | 14,404 | ||||
Research and development | (13,791) | (1,623) | (135) | (12,033) | ||||
Sales and Marketing | (20,338) | (2,253) | (1,234) | (16,851) | ||||
General and Administrative | (15,191) | (5,463) | (56) | (9,672) | ||||
Total Operating Expenses | (49,320) | (9,339) | (1,425) | (38,556) | ||||
Operating Loss | $ | (36,655) | 9,365 | 3,138 | (24,152) | |||
Financing expenses | 4,954 | - | - | 4,954 | ||||
Income Tax | 105 | - | - | 105 | ||||
Net Loss | $ | (41,714) | 9,365 | 3,138 | (29,211) | |||
Reconciliation of Operating Loss, Net Loss and Operating Expenses to Adjusted | ||||||||
Operating Loss, Net Loss and Operating Expenses (Non-GAAP) | ||||||||
Twelve months ended December 31, 2024 | ||||||||
GAAP | Stock-Based | Amortization of | Non -GAAP | |||||
Cost of Revenues | $ | 13,773 | (13) | (5,086) | 8,674 | |||
Gross Profit | 13,267 | 13 | 5,086 | 18,366 | ||||
Research and development | 24,179 | (3,296) | (238) | 20,645 | ||||
Sales and Marketing | 26,350 | (4,890) | (1,183) | 20,277 | ||||
General and Administrative | 20,482 | (7,597) | (1,649) | 11,236 | ||||
Total Operating Expenses | 71,011 | (15,783) | (3,070) | 52,158 | ||||
Operating Loss | $ | (57,744) | 15,796 | 8,156 | (33,792) | |||
Financing expenses | (13,145) | - | - | (13,145) | ||||
Income Tax | (1,852) | - | - | (1,852) | ||||
Net Loss | $ | (42,747) | 15,796 | 8,156 | (18,795) | |||
DarioHealth Corporate Contact
Zoe Harrison
VP, Accounting and Corporate Development
irteam@dariohealth.com
DarioHealth Investor Relations Contact
Michael Lipari
SVP Corporate Development
irteam@dariohealth.com
+1-201-785-6310
Logo - https://mma.prnewswire.com/media/2866807/5869548/Dario_Logo.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/dariohealth-reports-fourth-quarter-and-full-year-2025-financial-and-operating-results-302718542.html
SOURCE DarioHealth Corp.